Is Dr Lal Pathlabs overvalued or undervalued?

As of March 21, 2024, Dr. Lal Pathlabs is considered very expensive and overvalued with a PE ratio of 48.96, despite being more attractive than some competitors like Max Healthcare and Apollo Hospitals, but its growth potential is questionable given a PEG ratio of 1.36 and a low dividend yield of 1.05%.

As of 21 March 2024, the valuation grade for Dr. Lal Pathlabs has moved from expensive to very expensive, indicating a significant shift in its market positioning. The company is currently deemed overvalued. Key ratios include a PE ratio of 48.96, an EV to EBITDA of 32.84, and a Price to Book Value of 10.98, all of which suggest a premium valuation compared to its peers.<BR><BR>In comparison, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals stands at 69.03, illustrating that Dr. Lal Pathlabs, despite its high valuation, is still more attractive than some competitors. However, with a PEG ratio of 1.36 and a dividend yield of only 1.05%, the stock's growth potential does not justify its current price. Recent performance shows that while Dr. Lal Pathlabs has outperformed the Sensex over the past week and month, it lags behind in the year-to-date and one-year returns, reinforcing the notion that it may be overvalued in the current market context.

how big is Dr Lal Pathlabs?

As of Jun 06, Dr Lal Pathlabs Ltd has a market capitalization of 23,827.41 Cr, with recent net sales of 2,461.40 Cr and net profit of 487.10 Cr for the latest four quarters.

Market Cap: As of Jun 06, Dr Lal Pathlabs Ltd has a market capitalization of 23,827.41 Cr, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Dr Lal Pathlabs reported a sum of Net Sales of 2,461.40 Cr and a sum of Net Profit of 487.10 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 1,849.28 Cr, while the Total Assets amount to 2,411.10 Cr.

What does Dr Lal Pathlabs do?

Dr. Lal PathLabs Ltd is a healthcare services company specializing in laboratory testing and diagnostic services, with a market cap of Rs 23,900 Cr and a net profit of 155 Cr for the quarter ending March 2025. The company was founded in 1995 and transitioned to a public limited company in 2015.

Overview: <BR>Dr. Lal PathLabs Ltd is a healthcare services company operating in the large-cap market segment, primarily engaged in laboratory testing and diagnostic services.<BR><BR>History: <BR>Dr. Lal PathLabs Ltd was incorporated as a Private Limited Company on February 14, 1995, in Delhi. It transitioned to a Public Limited Company and changed its name on August 19, 2015. The most recent quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 603 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 155 Cr (Quarterly Results - Mar 2025) <BR>- Market cap: Rs 23,900 Cr (Large Cap) <BR><BR>Key Metrics: <BR>- P/E: 49.00 <BR>- Industry P/E: 54 <BR>- Dividend Yield: 0.84% <BR>- Debt Equity: -0.46 <BR>- Return on Equity: 22.42% <BR>- Price to Book: 11.00 <BR><BR>Contact Details: <BR>Address: E-2 Block Sector 18, Rohini New Delhi New Delhi : 110085 <BR>Tel: 91-011-3024 4149 <BR>Email: cs@lalpathlabs.com <BR>Website: http://www.lalpathlabs.com

When is the next results date for Dr Lal Pathlabs?

No Upcoming Board Meetings

Has Dr Lal Pathlabs declared dividend?

Yes, Dr Lal Pathlabs Ltd has declared a dividend of 60% (₹6 per share) with an ex-date of June 6, 2025, and a dividend yield of 0.84%. The company has shown positive total returns over various periods, particularly in the long term.

Dr Lal Pathlabs Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 6<BR>- Ex-date: 06 Jun 25<BR><BR>Dividend Yield: 0.84%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -6.55%, the dividend return was 0.38%, resulting in a total return of -6.17%.<BR><BR>Over the past year, the price return was 3.48%, the dividend return was 0.86%, leading to a total return of 4.34%.<BR><BR>In the 2-year period, the price return stood at 41.45%, with a dividend return of 2.26%, culminating in a total return of 43.71%.<BR><BR>For the 3-year period, the price return was 31.1%, the dividend return was 2.74%, resulting in a total return of 33.84%.<BR><BR>In the last 4 years, the price return was -0.41%, with a dividend return of 2.35%, leading to a total return of 1.94%.<BR><BR>Over the past 5 years, the price return was 73.98%, the dividend return was 5.47%, resulting in a total return of 79.45%.<BR><BR>Overall, Dr Lal Pathlabs has shown a consistent ability to declare dividends, with a notable yield of 0.84%. The total returns over various periods indicate a generally positive performance, particularly in the longer term, highlighting the company's growth and profitability.

Who are the peers of the Dr Lal Pathlabs?

Dr Lal Pathlabs' peers include Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Health, Suven Life Sciences, Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, and Tarsons Products. Management risk varies from excellent to below average, with growth and capital structure generally rated as good to excellent, while Suven Life Sciences leads in 1-year returns at 118.45%, and Dr Lal Pathlabs has a modest return of 0.15%.

Peers: The peers of Dr Lal Pathlabs are Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Suven Life Scie., Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, and Tarsons Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, Laxmi Dental, and Thyrocare Tech., while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, and Suven Life Scie. Average management risk is present at Krsnaa Diagnost., and Below Average management risk is noted for Suven Life Scie. Growth is Below Average for Dr Lal Pathlabs, Syngene Intl., Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Average growth is seen at Poly Medicure, Indegene, and the rest. Good growth is observed at Laxmi Dental. Capital Structure is Excellent for Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Krsnaa Diagnost., and the rest, while Good capital structure is noted for Laxmi Dental.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 118.45%, while the peer with the lowest is Tarsons Products at -23.12%. Dr Lal Pathlabs has a 1-year return of 0.15%, which is significantly lower than Suven Life Scie. and higher than Tarsons Products. Additionally, Metropolis Healt and Suven Life Scie. have negative six-month returns.

Who are in the management team of Dr Lal Pathlabs?

As of March 2023, the management team of Dr Lal Pathlabs includes Arvind Lal (Chairman & Executive Director), Vandana Lal (Executive Director), Om Prakash Manchanda (Managing Director), and several independent and non-executive directors, totaling 14 members who guide the company's governance and strategy.

As of March 2023, the management team of Dr Lal Pathlabs includes the following individuals:<BR><BR>1. Arvind Lal - Chairman & Executive Director<BR>2. Vandana Lal - Executive Director<BR>3. Om Prakash Manchanda - Executive Director & Managing Director<BR>4. Archana Lal Erdmann - Non-Executive Director<BR>5. Rahul Sharma - Non-Executive Director<BR>6. Anoop Mahendra Singh - Independent Director<BR>7. Harneet Singh Chandhoke - Independent Director<BR>8. Sunil Varma - Lead Independent Director<BR>9. Saurabh Srivastava - Independent Director<BR>10. Somya Satsangi - Independent Director<BR>11. Rohit Bhasin - Independent Director<BR>12. Arun Duggal - Independent Director<BR>13. Gurinder Singh Kalra - Independent Non-Executive Director<BR>14. Rajit Mehta - Independent Non-Executive Director<BR><BR>This team encompasses a mix of executive, non-executive, and independent directors, contributing to the governance and strategic direction of the company.

Who are the top shareholders of the Dr Lal Pathlabs?

The top shareholders of Dr Lal Pathlabs include Arvind Lal with 30.8%, foreign institutional investors holding 23.91%, mutual funds at 12.84%, and Invesco Oppenheimer International Growth Fund as the largest public shareholder with 3.52%. Individual investors own a total of 4.11%.

The top shareholders of Dr Lal Pathlabs include the promoters, with Arvind Lal being the individual with the highest holding at 30.8%. Additionally, institutional investors play a significant role, with foreign institutional investors (FIIs) holding 23.91% through 326 different entities. Mutual funds are represented by 26 schemes, accounting for 12.84% of the shares. The highest public shareholder is Invesco Oppenheimer International Growth Fund, which holds 3.52%. Individual investors collectively own 4.11% of the company.

Are Dr Lal Pathlabs latest results good or bad?

Dr. Lal PathLabs' latest results are good, with record revenue of ₹730.60 crores and a net profit increase of 16.41% to ₹150.40 crores for the quarter ending September 2025, indicating strong performance and operational efficiency.

Dr. Lal PathLabs has reported strong results for the quarter ending September 2025, indicating a positive performance overall. The company achieved record revenue of ₹730.60 crores, reflecting a year-on-year growth of 10.66%. This marks the highest quarterly sales in the company's history. Additionally, the consolidated net profit increased by 16.41% year-on-year to ₹150.40 crores, showcasing robust profitability.<BR><BR>Operating margins remained stable at 30.67%, consistent with the previous year, which demonstrates effective cost management despite inflationary pressures. The net profit margin also improved, reaching 20.83%, up 102 basis points from the same quarter last year.<BR><BR>Overall, the results highlight Dr. Lal PathLabs' ability to maintain strong business traction and operational efficiency in the growing healthcare diagnostics market. Given these factors, the latest results can be considered good, reflecting both revenue expansion and profitability growth.

How has been the historical performance of Dr Lal Pathlabs?

Dr Lal Pathlabs has exhibited consistent growth in net sales and profits, with net sales increasing from ₹1,203.40 Cr in March 2019 to ₹2,461.40 Cr in March 2025, and profit after tax rising from ₹200.50 Cr to ₹492.20 Cr during the same period. The company's earnings per share improved from 23.91 to 58.27, reflecting strong overall performance.

Answer:<BR>The historical performance of Dr Lal Pathlabs shows a consistent growth trajectory in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Dr Lal Pathlabs has demonstrated robust growth in net sales, rising from 1,203.40 Cr in March 2019 to 2,461.40 Cr in March 2025. The total operating income followed a similar upward trend, reaching 2,461.40 Cr in March 2025, up from 1,203.40 Cr in March 2019. Operating profit, excluding other income, also increased significantly, from 343.60 Cr in March 2020 to 695.50 Cr in March 2025. The profit before tax saw a substantial rise from 300.60 Cr in March 2019 to 624.70 Cr in March 2025, while profit after tax increased from 200.50 Cr to 492.20 Cr in the same period. The company's earnings per share (EPS) improved markedly from 23.91 in March 2019 to 58.27 in March 2025, reflecting enhanced profitability. On the balance sheet, total assets grew from 1,351.46 Cr in March 2020 to 2,630.17 Cr in March 2025, while total liabilities rose from 1,351.46 Cr to 2,630.17 Cr, indicating a proportional increase in both assets and liabilities. Cash flow from operating activities also showed improvement, increasing from 283.00 Cr in March 2020 to 568.00 Cr in March 2025, although the net cash outflow was recorded at -68.00 Cr in March 2025. Overall, Dr Lal Pathlabs has shown a strong performance with consistent growth in sales, profits, and assets over the years.

Should I buy, sell or hold Dr Lal Pathlabs?

Is Dr Lal Pathlabs technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish, supported by daily moving averages, though caution is advised due to mixed signals from weekly indicators.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a bullish trend. However, the weekly MACD and Bollinger Bands are both mildly bearish, suggesting some caution in the short term. The monthly indicators, including MACD and Bollinger Bands, are bullish, indicating a stronger long-term outlook. Overall, while there are mixed signals, the prevailing trend is mildly bullish, driven primarily by daily moving averages.

Which are the latest news on Dr Lal Pathlabs?

Why is Dr Lal Pathlabs falling/rising?

As of 04-Dec, Dr Lal Pathlabs Ltd's stock price is rising to 3,031.00, indicating a potential recovery in investor sentiment after recent declines. Despite short-term mixed signals, the company's strong financial health and positive quarterly results support its upward movement.

As of 04-Dec, Dr Lal Pathlabs Ltd's stock price is rising, currently at 3,031.00, reflecting an increase of 34.75 (1.16%). This upward movement follows a trend reversal after two consecutive days of decline, indicating a potential recovery in investor sentiment. The stock has outperformed its sector by 1.29% today, which suggests that it is gaining traction compared to its peers.<BR><BR>Despite a recent decline over the past week and month, where the stock fell by 2.71% and 3.84% respectively, the year-to-date performance remains positive at 1.37%. The company has demonstrated strong financial health, with a high return on equity (ROE) of 20.98% and a low debt-to-equity ratio, which enhances investor confidence. Furthermore, the company has reported positive results for the last three consecutive quarters, with a significant growth of 20.03% in profit after tax (PAT) over the latest six months and record high net sales and PBDIT for the most recent quarter.<BR><BR>Additionally, the stock's current price is above its 200-day moving average, although it is below the shorter-term moving averages, indicating mixed signals in the short term. The liquidity of the stock remains adequate for trading, despite a decrease in delivery volume, which may suggest a temporary pullback in investor participation. Overall, the combination of positive financial results and a recent trend reversal contributes to the stock's rising price.